BRAF and thyroid cancer: Aim of the present study was to test the effect of PLX4720 on the secretion of CXCL8 in normal human thyroid (NHT) cells, in the BCPAP, 8305C and 8505C thyroid cancer cell line harboring the BRAF V600e mutation and in the TPC-1 thyroid cancer cell line bearing the RET/PTC re-arrangement.